© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Tara K. Iyer, MD
Articles
How Primary Providers Can Prevent the Broader Health Impacts of VMS
March 28, 2025
Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).
Breaking Down the Science: Mechanisms of Action for New VMS Therapies
March 28, 2025
Panelists discuss how emerging therapies demonstrate promising efficacy data while highlighting the adverse metabolic and cardiovascular consequences associated with untreated vasomotor symptoms (VMS).
Beyond Hormone Therapy: Effective Alternatives for Managing Menopausal Symptoms
March 28, 2025
Panelists discuss how previous therapies lacked efficacy for vasomotor symptoms, while new treatments fezolinetant and elinzanetant offer superior effectiveness, with elinzanetant specifically addressing additional symptoms beyond the primary condition.
Understanding VMS in Menopause: Prevalence and Impact
March 28, 2025
Panelists discuss how vasomotor symptoms (VMS) can persist for years with variable manifestations, significantly disrupting both social and professional spheres, resulting in multibillion-dollar economic losses through decreased productivity and increased insurance costs.